16 May 2025
IJN CEO Prof Ezani says IJN has shifted to mostly generics, but still provides some new innovator drugs due to existing contracts and the need to uphold IJN's reputation as a top cardiovascular hospital. Government referrals to IJN have dropped “slightly”.